The CLL6 RESIDUUM trial was a phase III randomized clinical trial of the ALLG and the FILO. Eligibility criteria were CLL patients with detectable residual disease after front-line ICT according to iwCLL guidelines [7]. Patients should have received at least 4 and at most 6 cycles of FCR. Residual disease was considered when detected at a level of at least 10–4 in multiparameter flow cytometry of peripheral blood or bone marrow, or when visualized through radiological evaluation.
